ArticleLancet regional health. Americas2023

Cost-effectiveness analysis of extended thromboprophylaxis with rivaroxaban versus no prophylaxis in high-risk patients after hospitalisation for COVID-19: an economic modelling study.

Caroline Cândida Carvalho de Oliveira et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.